Principal Investigator
Ellen Koo
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20221238
Clinical Trial Summary
A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Administration with Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Descemetorhexis in Subjects with Fuchs Endothelial Corneal Dystrophy
Phase
TBD
Funding Agency/Sponsor
Industry
Disease
Other
Contact Information
Study Contact
Olufemi Sangoyomi
Phone Number
+1 (561) 3558985
Email
oas77@miami.edu